Cangrelor versus Oral P2Y12 Inhibitors during Extracorporeal Membrane Oxygenation after Refractory Cardiac Arrest Related to Acute Coronary Syndrome (ISTH 2026) - May 25, 2026 - Abstract #PB3011; Pres time: Jul 14, 2026; 01:45 PM - 02:45 PM; Location: Exhibition Hall- Poster Area; "Clopidogrel and ticagrelor are the gold-standard, while intravenous cangrelor, with its short half-life, is easier to use in intensive care unit (ICU). Cangrelor regimen may represent a more flexible antiplatelet strategy in this high-bleeding and high- thrombotic risk population and warrant confirmation in prospective randomized studies. Table or Figure Upload (1) Figure: Antithrombotic treatment in refractory cardiac arrest related to acute coronary syndrome: cangrelor-based regimen versus oral P2Y 12 inhibitor Page 2 Table or Figure Upload (2) Table: Baseline characteristics, bleeding and thrombotic outcomes according to P2Y 12 inhibitor regimen during VA-ECMO DOI*10.1016/j.rpth.2026.105631"
Acute Coronary Syndrome • Cardiovascular • Hematological Disorders • Thrombosis
|
|
Georges Abi Abdallah 1; Lucas Buissez 2; Anne Céline Martin 3; Gersende Fave 2; Emmanuel Rozenberg 2; Maxime Renaux 2; Etienne Puymirat 3; Anne François 4; Caroline FRITZ 5; Anne Godier 1
|